Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Kobo Resources Announces Closing of Non-Brokered Private Placement for Gross Proceeds of $5.5 Million and Engagement of Atrium Research
Sranan Gold Mobilizes Second Drill Rig onto its Tapanahony Project Targeting 5,000-Metres along the Poeketi Zone.
Anteros Metals Advances Seagull Project Targeting Natural Hydrogen, Helium and PGE Mineralization and Engages Chibougamau Drilling
